주메뉴바로가기 본문바로가기
Generic Peptides

PEPTIDES

Generic Peptides

  1. HOME
  2. PEPTIDES
  3. Generic Peptides
Our Generic Peptides
Teriparatide Acetate
Cat #
Introduction
Teriparatide, sold under the brand name Forteo, is a form of parathyroid hormone (PTH) consisting of the first (N-terminus) 34 amino acids, which is the bioactive portion of the hormone. It is an effective anabolic (promoting bone formation) agent used in the treatment of some forms of osteoporosis. It is also occasionally used off-label to speed fracture healing. Teriparatide is identical to a portion of human parathyroid hormone and intermittent use activates osteoblasts more than osteoclasts, which leads to an overall increase in bone.
Sequence
C181H291N55O51S2
MW
4117.77
Reference
1. "Drug Approval Package: Bonsity". U.S. Food and Drug Administration (FDA). 26 February 2020. Retrieved 14 September 2020.

2. "Summary Basis of Decision (SBD) for Osnuvo". Health Canada. Retrieved 29 May 2022.

3. Lisbeth Tristan de Brea (18 September 2018). "Nota de Seguridad de Medicamentos" (PDF). Panama: Directora Nacional de Farmacia y Drogas.

4. "Teriparatide Use During Pregnancy". Drugs.com. 25 November 2019. Retrieved 14 September 2020.

5. "Forsteo EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 26 June 2020.
Fields of application
It is effective in growing bone (e.g., 8% increase in bone density in the spine after one year) and reducing the risk of fragility fractures. When studied, teriparatide only showed bone mineral density (BMD) improvement during the first 18 months of use. Teriparatide should only be used for a period of 2 years maximum. After 2 years, another agent such a bisphosphonate or denosumab should be used in cases of osteoporosis although repeat administration has been used in hypophosphatasia, where bisphosphonates are contraindicated.

Teriparatide cuts the risk of hip fracture by more than half but does not reduce the risk of arm or wrist fracture.
Synonyms
Structure